Suraksha Diagnostic Ltd (SURAKSHA) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Suraksha Diagnostic Ltd demonstrated strong revenue growth, driven by increased patient volumes and network expansion, despite facing significant operational disruptions.
- The company's profitability was temporarily impacted by adverse weather conditions, specifically heavy rainfall and floods in its core market, which led to a revenue shortfall of INR 3.5 to 4 crores.
- Strategic expansion remains a key focus, with the addition of 3 new centers in Q2, bringing the total network to 63 centers. The company is on track to add 12 to 15 new centers in FY26.
- A landmark achievement during the quarter was the launch of Suraksha Genomics, a strategic foray into advanced genetic and molecular testing, aimed at capturing a high-potential market segment in Eastern India.
- Management reaffirmed its full-year guidance, expressing confidence in achieving 15% revenue growth for FY26 with an EBITDA margin between 33% and 34%, expecting a recovery in the second half of the year as new centers mature and seasonal impacts subside.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.